BPC-157 Dosage and Protocol: What the Evidence Actually Says

The Peptide Everyone's Talking About

Scroll through any fitness or biohacking forum right now and you'll find someone crediting BPC-157 for healing a torn tendon, fixing their leaky gut, or recovering from a knee injury in half the time. It's the peptide that seems to do everything — and that alone should make you at least a little skeptical.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, meaning it's a short chain of 15 amino acids. It was derived from a protein naturally found in human gastric juice — so it does have a biological origin story, even if the version people are injecting is lab-made. The research is genuinely interesting. It's also mostly in rats. Those two facts need to coexist in your head as you read this.

This guide covers what BPC-157 dosage actually looks like in practice, which administration routes make sense for which goals, how to think about cycling, and what the honest evidence shows about injury repair and gut health. No hype. Just the clearest picture currently available.

What Is BPC-157, Really?

BPC-157 was first isolated from human gastric juice in the 1990s by Croatian researcher Predrag Sikiric and his team at the University of Zagreb. The peptide is a fragment of a larger protein called Body Protection Compound, which plays a role in protecting the gastrointestinal lining. The "157" refers to the specific amino acid sequence position in that parent protein.

Think of it as a signaling molecule that tells your tissues to repair themselves faster. Your body already produces something similar in your gut — BPC-157 just amplifies and extends that signal. It doesn't introduce a foreign mechanism. It borrows one your body already uses.

The primary mechanisms researchers have identified include promoting angiogenesis (the growth of new blood vessels into damaged tissue), upregulating growth hormone receptors, modulating nitric oxide production, and influencing several growth factors involved in tendon and ligament repair. It also appears to have a protective effect on the gastrointestinal mucosa (the inner lining of your gut), which is where the gut health use case comes from.

How BPC-157 Dosage Works: The Basics

Here's where things get complicated — because there are no FDA-approved human dosing protocols for BPC-157. Every dosing guideline you'll find is extrapolated from animal studies, anecdotal reports, and the clinical judgment of practitioners who've been working with peptides for years. That's the honest starting point.

With that caveat clearly on the table, the dosing ranges most commonly reported in the literature and in clinical practice are as follows:

Standard BPC-157 Dosage Range

• Low dose: 1-2 mcg per kilogram of body weight per day
• Moderate dose: 2-10 mcg per kilogram of body weight per day
• Common clinical range reported: 200-500 mcg per day for a 70-80 kg adult

Most of the animal studies use doses in the range of 10 mcg/kg, administered once or twice daily. When you scale that to a 75 kg human, you get roughly 750 mcg per day — which is on the higher end of what most practitioners use. Many clinicians working with BPC-157 in practice report that 250-500 mcg once daily appears to be the practical sweet spot for most applications, though this is experience-based, not RCT-derived.

The reality check: we don't have dose-response data in humans. We don't know if more is better, or if there's a ceiling effect. What we do know is that the peptide appears to have a wide safety margin in animal models — but you are not a rat, and extrapolation only goes so far.

BPC-157 Administration Routes: Which One Actually Makes Sense?

This is where the protocol gets more nuanced, because the right administration route depends entirely on what you're trying to treat. BPC-157 is not one-size-fits-all.

Subcutaneous Injection

The most common route, and the one with the most clinical and anecdotal data behind it. You inject under the skin, typically near the site of injury for musculoskeletal issues (tendon, ligament, joint). The peptide gets absorbed into systemic circulation quickly and also has a local effect near the injection site.

For injury repair specifically, injecting near the affected tissue — not necessarily directly into it — appears to produce better outcomes based on the available rodent studies. Think: near the knee, not into the knee joint itself.

Intramuscular Injection

Occasionally used for deeper tissue injuries. Less common than subcutaneous because subcutaneous is easier and appears equally effective in most contexts. Some practitioners prefer IM for larger muscle injuries specifically.

Oral / BPC-157 Capsules

This route has a dedicated use case: gut health. BPC-157 given orally is largely broken down before reaching systemic circulation, which means it has minimal effect on tendons or muscles. But it has a direct effect on the gastrointestinal mucosa. If gut healing is your goal — inflammatory bowel disease, leaky gut, NSAID-induced damage — oral administration is the route that makes biological sense.

Oral doses in rat models have ranged widely, but the equivalent human dose extrapolated from studies tends to run 500 mcg to 1000 mcg daily when taken orally, with the higher end partially compensating for poor bioavailability.

Intranasal

Some practitioners use intranasal BPC-157 for neurological and brain health applications, given the proximity to the central nervous system via the olfactory pathway. The evidence here is thinner than for musculoskeletal or gut applications. Interesting mechanism; not yet robust data.

BPC-157 Protocol and Cycling: How Long Should You Use It?

Another area where the evidence is honest about its limits. There's no established cycling protocol validated in human trials. What exists is a collection of practitioner-derived frameworks that have emerged over years of use.

Typical Protocol Duration

• Acute injury: 4-6 weeks of daily dosing, then reassess
• Chronic injury / gut healing: 8-12 weeks is commonly reported, sometimes longer
• Maintenance / prevention: Some practitioners suggest cycling on for 4-6 weeks, off for 4-6 weeks, though this is not evidence-based

Why Cycle at All?

Here's the thing: we don't have clear evidence that BPC-157 causes receptor downregulation or tolerance the way some other peptides might. The rationale for cycling is more precautionary — we simply don't have long-term safety data in humans, so periodic breaks are a reasonable risk-management strategy, not a necessity proven by data.

BPC-157 is also not a steroid or a hormone. It's a signaling peptide. The mechanism isn't the same as anabolic compounds that cause feedback suppression. That said, "we haven't seen a problem yet" is not the same as "it's definitely safe long-term." Those are different statements and it's worth keeping them separate in your mind.

What Does the Evidence Actually Show?

Ready for some science that won't put you to sleep? The key word throughout this section is: most of this is animal data.

Tendon and Ligament Repair

This is arguably the strongest use case. A 2006 study in the American Journal of Sports Medicine found that BPC-157 significantly accelerated Achilles tendon healing in rats, with treated tendons showing faster collagen organization and higher tensile strength at 14 and 21 days compared to controls. A follow-up study in the same model found the effect persisted even with large transection injuries.

Multiple studies have shown BPC-157 upregulates tendon-specific growth factors and promotes tendon fibroblast survival and proliferation. The proposed mechanism — upregulation of the FAK-paxillin pathway, which is central to tendon cell adhesion and migration — is biologically coherent. The research group in Zagreb has produced a substantial body of work here, though it's worth noting most of it comes from a single lab.

Gut Health and GI Protection

The gastric origin of BPC-157 gives it a credible gut health story. Studies have shown it accelerates healing of gastric ulcers, reduces NSAID-induced gut damage, and protects against colitis in animal models. A 2004 paper in the Journal of Ethnopharmacology found BPC-157 protected against various forms of experimentally induced intestinal damage.

One particularly interesting finding: BPC-157 appears to counteract gut damage caused by NSAIDs like ibuprofen. If you're someone taking anti-inflammatories for an injury and you're also trying to heal that injury, there's a certain poetic logic to pairing BPC-157 — though again, this is rodent data.

Muscle and Bone Repair

Animal studies have also shown accelerated healing of muscle tears, bone fractures, and ligament injuries. The angiogenesis effect appears central here: BPC-157 promotes the growth of new blood vessels into injured tissue, which is a prerequisite for tissue repair. More blood flow means more nutrients, more oxygen, faster healing. Makes sense mechanistically. Demonstrated in animals. Not yet confirmed in human RCTs.

Anti-Inflammatory Effects

BPC-157 modulates nitric oxide synthesis and appears to reduce local inflammation without broadly suppressing immune function the way corticosteroids do. This is a meaningful distinction. Chronic low-grade inflammation is one of the drivers of poor healing in connective tissue — blunting it locally while keeping systemic immune function intact is theoretically quite useful.

The Reality Check

You are not a mouse. You are also not a rat. The overwhelming majority of BPC-157 research — including the most compelling injury repair data — is in rodents. That doesn't mean the findings won't translate to humans. Many things that work in animal models do eventually prove out in human trials. But we're not there yet with BPC-157.

There are no completed Phase II or Phase III human clinical trials for BPC-157. A Phase II trial was initiated in the early 2000s for inflammatory bowel disease but did not progress to completion. The biohacking community has largely run ahead of the clinical evidence, which doesn't mean they're wrong — it means they're doing a version of uncontrolled self-experimentation, and the results are anecdote, not data.

The internet wants this to be a magic healing peptide. The research is genuinely promising. Those are both true, and you should hold them at the same time.

Who Is BPC-157 Actually Right For?

Based on the available evidence, the most reasonable candidates are:

• Athletes and active adults with persistent tendon or ligament injuries that haven't responded to standard conservative care (physical therapy, rest, NSAIDs)
• People with gut issues — particularly those with symptoms consistent with GI inflammation, NSAID-induced gut damage, or inflammatory bowel conditions — who are exploring adjunctive support beyond standard treatment
• Adults in their 30s-60s who are trying to maintain training capacity as recovery slows with age
• People who have done their homework, understand this is off-label and not FDA-approved, and want to work with a clinician rather than self-sourcing unverified peptides from grey-market suppliers

BPC-157 is probably not the right first step if you have an acute injury that hasn't been properly evaluated, if you have untreated underlying conditions, or if you're hoping it's a shortcut around physical therapy and rehabilitation. It's an adjunct, not a replacement.

Risks and Side Effects

The safety profile in animal studies is remarkably clean — unusually so for a biologically active compound. But again: you are not a rat.

• No significant toxicity has been observed in animal studies even at high doses
• Injection site reactions (redness, mild swelling) are the most commonly reported side effects in human anecdote
• Nausea is occasionally reported, more commonly with oral dosing
• No known hormonal suppression based on current evidence, unlike anabolic peptides
• Unknown long-term safety in humans — the most important caveat of all
• Source quality matters enormously: BPC-157 obtained from unregulated grey-market suppliers may be mislabeled, underdosed, contaminated, or not BPC-157 at all

Medical supervision isn't optional here. It's how you manage the unknowns.

How to Get Started with BPC-157 at Healthspan

Healthspan's Longevity Optimization program is the clinical framework through which BPC-157 and other peptide protocols are evaluated and managed. This isn't a DTC supplement checkout — it's a supervised clinical process.

Here's what that actually looks like: you start with a comprehensive intake and lab panel to establish your baseline health picture. A Healthspan clinician reviews your goals, your injury or gut health history, and any relevant biomarkers. If BPC-157 is appropriate for you, you'll receive a protocol that includes pharmaceutical-grade peptide (not grey-market), a specific dosing recommendation based on your weight and goals, guidance on administration route and technique, and scheduled follow-ups to assess response and adjust if needed.

The follow-up piece matters more than it sounds. BPC-157 isn't a set-it-and-forget-it protocol. Knowing when to stop, when to adjust, and whether what you're experiencing is a normal response or a reason to reassess — that's what clinical oversight gives you that a forum post cannot.

If you're also dealing with chronic inflammation, metabolic issues, or broader recovery challenges, your clinician can discuss whether adjunctive protocols like Low Dose Naltrexone (LDN) — which has its own anti-inflammatory and immune-modulating evidence base — might be worth considering alongside BPC-157.

The starting point is a consultation. That's where the protocol actually begins.

Frequently Asked Questions About BPC-157 Dosage and Protocol

What is the recommended BPC-157 dosage for injury repair?

The most commonly used clinical range for injury repair is 250-500 mcg per day via subcutaneous injection, administered near (not into) the site of injury. This is extrapolated from animal studies using approximately 10 mcg/kg body weight. There are no FDA-approved human dosing guidelines. Work with a clinician to establish a protocol specific to your body weight and injury type.

How long does it take for BPC-157 to work?

In animal studies, measurable improvements in tendon healing appear within 2-3 weeks of daily dosing. Anecdotal human reports vary widely — some people report noticing changes in pain and mobility within 1-2 weeks, while others report gradual improvement over 4-6 weeks. Gut health applications may take 4-8 weeks to show meaningful change. Individual response varies.

Should I inject BPC-157 near the injury site or systemically?

For musculoskeletal injuries, injecting subcutaneously near the affected tissue appears to produce stronger local effects, based on animal research. You don't need to inject directly into the injury, just in the general area. For gut health, oral administration is the preferred route since systemic injection bypasses the gastrointestinal lining where you need the effect.

How long should a BPC-157 cycle last?

Most practitioners recommend 4-8 weeks for acute injuries and 8-12 weeks for chronic injuries or gut healing, followed by a break of similar length. There's no established human evidence for optimal cycle length. Cycling is primarily a precautionary strategy given limited long-term human safety data, not a response to demonstrated tolerance or receptor downregulation.

Can I take BPC-157 orally instead of injecting it?

Yes, but oral BPC-157 has different applications. Oral dosing is appropriate for gut health goals — it acts directly on the gastrointestinal lining without needing systemic absorption. For tendon, ligament, or muscle repair, oral dosing is not the preferred route because the peptide is largely broken down before reaching systemic circulation, limiting its effect on non-GI tissue.

Is BPC-157 legal to buy and use?

BPC-157's legal status is a grey area. It is not FDA-approved for any indication and cannot be sold as a supplement or drug in the United States. It exists in a regulatory grey zone as a research compound. Obtaining it through a licensed clinician who can prescribe compounded peptides is the clearest path to sourcing a verified, pharmaceutical-grade product. Self-sourcing from unregulated online vendors carries significant quality and safety risks.

Does BPC-157 cause any hormonal suppression?

Based on current evidence, BPC-157 does not cause hormonal suppression. It is not an anabolic steroid or a peptide that directly stimulates or suppresses the hypothalamic-pituitary axis. Unlike compounds like testosterone or GH secretagogues, BPC-157 does not create a feedback loop that shuts down endogenous hormone production. That said, long-term human data is limited, which is why clinical monitoring matters.